Illumina Expands Use of HiSeq X™ Sequencing System to Include Non-Human Species
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Canaccord Genuity Reiterates Buy on Illumina (ILMN) Following 3Q15 Preliminary Results
October 6, 2015 8:37 AM EDTCanaccord Genuity reiterated a Buy rating and $250.00 price target on Illumina (NASDAQ: ILMN) following the company's preliminary 3Q15 earnings results. ILMN reported preliminary 3Q15 revenues of ~$550M compared to the Streets $569M, citing weakness in Asia and Europe and desktop sequencers.
Analyst... More
Piper Jaffray Cuts Price target on Illumina (ILMN) Following Preliminary 3Q15 Results
October 6, 2015 8:01 AM EDTPiper Jaffray maintained an Overweight rating on Illumina (NASDAQ: ILMN), and cut the price target to $220.00 (from $230.00), following the announced preliminary 3Q15 results. Illumina issued results with revenue increasing ~14% yoy to $550M, below in-line $569.2M estimates and 3Q15 EPS below the Street's $0.83. Management attributed the miss to a... More
Illumina (ILMN) Announces Expanded HiSeq X Sequencing System Rights for non-Human Species
October 6, 2015 6:31 AM EDTIllumina (Nasdaq: ILMN) announced it has expanded the rights of use for the HiSeq X Sequencing System to allow customers to perform whole-genome sequencing of non-human species. The updated rights of use will take effect immediately for existing customers of the HiSeq X Ten and HiSeq X Five, and will apply to all new customers of the sequencing systems.
Driven by the worlds first $1,000 human... More
